Article citationsMore>>

A. Maillet, L. Guilleminault, E. Lemarié, S. Lerondel, N. Azzopardi, J. Montharu, N. Congy-Jolivet, P. Reverdiau, B. Legrain, C. Parent, D.-H. Douvin, J. Hureaux, Y. Courty, M. De Monte, P. Diot, G. Paintaud, A. Le Pape, H. Watier and N. Heuzé-Vourc’h, “The Airways, a Novel Route for Delivering Monoclonal Antibodies to Treat Lung Tumors,” Pharmaceutical Research, Vol. 28, No. 9, 2011, pp. 2147-2156. Doi:10.1007/s11095-011-0442-5

has been cited by the following article:

• TITLE: Monoclonal Antibodies: An Emerging Class of Therapeutics in Non Small Cell Lung Cancer

  AUTHORS: L. Guilleminault, E. Lemarié, N. Heuzé-Vourc’h

  KEYWORDS: Monoclonal Antibody; Targeted Therapy; Non Small Cell Lung Cancer; Immunoglobulin

  JOURNAL NAME: Journal of Cancer Therapy, Vol.3 No.6, December 27, 2012

  ABSTRACT: Lung cancer is the leading cause of cancer-related deaths in industrialized countries and non small cell lung cancer (NSCLC) accounts for 85% of all lung cancers. Cisplatin doublet based chemotherapy, which is the recommended regimen in first line therapy in advanced or metastatic NSCLC, improves survival but in low proportion. Monoclonal antibodies (mAbs) are a novel promising therapeutic class used with great results in inflammatory diseases such as rheumatoid arthritis. Antibodies are natural proteins with modular structure, specific pharmacodynamics and pharmacokinetics and possibly produced against any antigens, thus giving them several advantages over small drug therapeutics. In solid tumors, therapeutic mAbs improved progression free survival (PFS) and overall survival (OS) of patients with breast and colon cancers and had considerably changed the treatment in clinical practice. In NSCLC, bevacizumab, an anti-VEGF mAb, and cetuximab, an anti-EGFR mAb, are the most studied antibodies. Bevacizumab acts on angiognenesis and improved PFS of non squamous NSCLC but in low proportion as shown in two large phase III trials. It was approved by European Medicines Agency (EMEA) and Food and Drug administration (FDA) as a first line therapy in combination with cisplatin doublet chemotherapy. Cetuximab slightly enhanced OS but did not improve PFS in two large phase III trials. These results added to high adverse effect lead to cetuximab refusal by EMEA and FDA in NSCLC. At first glance, the results of mAbs in NSCLC are somewhat disappointing, in contrast to the benefits obtained with mAb treatments in other solid tumors. However, many other mAbs directed against novel targets, such as IGF1-R or CTLA-4, and new mAbs targeting VEGFR and EGFR pathways with different pharmacodymamical and pharmacokinetic properties are under evaluation and may change our vision of taking care of patients with NSCLC. In conclusion, it seems that mAbs therapy in NSCLC clearly marks the start of a new era in NSCLC treatment, with promises in improving patient survival and quality of life.